company background image
FAEE logo

Faes Farma BATS-CHIXE:FAEE Stock Report

Last Price

€3.20

Market Cap

€1.0b

7D

0%

1Y

-15.9%

Updated

03 Oct, 2023

Data

Company Financials +

FAEE Stock Overview

Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. More details

FAEE fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

Faes Farma, S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Faes Farma
Historical stock prices
Current Share Price€3.20
52 Week High€3.80
52 Week Low€3.07
Beta0.52
1 Month Change0%
3 Month Change3.57%
1 Year Change-15.92%
3 Year Change-8.84%
5 Year Change-12.29%
Change since IPO62.17%

Recent News & Updates

Recent updates

Shareholder Returns

FAEEGB PharmaceuticalsGB Market
7D0%4.1%4.1%
1Y-15.9%0.8%10.9%

Return vs Industry: FAEE underperformed the UK Pharmaceuticals industry which returned -7.1% over the past year.

Return vs Market: FAEE underperformed the UK Market which returned -2.4% over the past year.

Price Volatility

Is FAEE's price volatile compared to industry and market?
FAEE volatility
FAEE Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement4.9%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.7%

Stable Share Price: FAEE has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine FAEE's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19331,764n/afaesfarma.com

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.

Faes Farma, S.A. Fundamentals Summary

How do Faes Farma's earnings and revenue compare to its market cap?
FAEE fundamental statistics
Market cap€1.00b
Earnings (TTM)€89.64m
Revenue (TTM)€468.68m

10.9x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FAEE income statement (TTM)
Revenue€468.68m
Cost of Revenue€160.06m
Gross Profit€308.62m
Other Expenses€218.98m
Earnings€89.64m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.29
Gross Margin65.85%
Net Profit Margin19.13%
Debt/Equity Ratio1.3%

How did FAEE perform over the long term?

See historical performance and comparison

Dividends

5.0%

Current Dividend Yield

40%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/03 19:00
End of Day Share Price 2023/07/06 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Faes Farma, S.A. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Álvaro Arístegui EchevarríaAhorro Corporación
Kamla SinghAlphaValue
Guilherme SampaioBanco BPI, S.A.